• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

Sep. 11, 2013

View Archived Issues

Hospira Chalks up First EU Biosimilar Antibody Approval

Hospira Inc. has reached a major milestone in the development of the biosimilar drugs market by gaining formal European Commission approval for Europe’s first biosimilar monoclonal antibody, Inflectra (infliximab), which is based on the blockbuster TNF-alpha inhibitor Remicade (infliximab). It represents the first major dent in the armor of the biotechnology industry’s most valuable franchise. Read More

Panel’s Hot Air Ends in Yes for Theravance/GSK COPD Bid

Panelists on the FDA’s Pulmonary-Allergy Drugs Advisory Committee that convened to decide about Anoro Ellipta, the inhaler product for chronic obstructive pulmonary disease (COPD), proved harder to satisfy than briefing documents might have led Glaxosmithkline plc (GSK) and partner Theravance Inc. to expect. Read More

Defactinib Moves into De Facto Phase III

Verastem Inc. demonstrated that lead candidate defactinib (VS-6063) remains on the fast track by initiating what it called a “registration-directed” trial of the cancer stem cell inhibitor in malignant pleural mesothelioma. The global, double-blind, placebo-controlled COMMAND (Control Of Mesothelioma with MAiNtenance Defactinib) trial plans to enroll 350 to 400 patients, with primary endpoints of progression-free survival (PFS) and overall survival (OS). Read More

Ethics Questions Trouble Pediatric Ethics Committee

What if a child were playing on the train tracks? What if there were a nuclear accident on the coastline? What if a safe were falling from the sky? The Pediatric Ethics Subcommittee of the FDA spent a second day of meetings deliberating on the questions posed by the agency, informed by speaker presentations from the previous day. Read More

Roche Licenses DNA Immunotherapies in Prostate Cancer, Hep-B

Basel, Switzerland-based Roche AG is partnering with Inovio Pharmaceuticals Inc. and will develop DNA-based vaccines INO-5150, targeting prostate cancer, and INO-1800, targeting hepatitis B. Read More

Kiadis’ ATIR Boosts Long-term Survival in Phase I/II HSCT Trial

LONDON – Kiadis Pharma BV announced positive results in a five-year follow-up of the Phase I/II study of ATIR, a cell therapy for enabling hematopoietic stem cell transplants from non-identical donors. Read More

mRNA Therapy Improves Heart Attack Survival in Mice

LONDON – Delivering synthetic messenger RNA that encodes the right growth factor directly to the heart muscle shortly after a heart attack can induce heart stem cells to divide and mature into new blood vessels, a new study has shown. Mice treated in that way showed a long-term increase in survival. Read More

Financings Roundup

• Nanoviricides Inc., of West Haven, Conn., said it met the listing standards of major U.S. stock exchanges after executing a 1-for-3.5 reverse split of its issued and outstanding common stock on Sept. 9, reflected at the opening of the Over-the-Counter Bulletin Board on Tuesday. Read More

Stock Movers

Read More

Pharma: Other News To Note

• Bayer Healthcare, of Whippany, N.J., a unit of Bayer AG, said it entered a strategic alliance with the Broad Institute in Cambridge, Mass., in the area of oncogenomics and drug discovery. Read More

Clinic Roundup

• Xenoport Inc., of Santa Clara, Calif., said it will advance XP23829, a fumaric acid ester compound that is a prodrug of monomethyl fumarate (MMF), in relapsing-remitting multiple sclerosis and/or psoriasis following positive preliminary results from two Phase I studies. Read More

Other News To Note

• Dipexium Pharmaceuticals LLC, of New York, made modifications to the formulation of Locilex (pexiganan acetate cream 1 percent), resulting in favorable chemical and physical stability according to an 18-month stability test by the manufacturer showing that it has a shelf life of at least 36 months at room temperature. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 9, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 9, 2025.
  • The Nasdaq Stock Exchange headquarters in New York

    Omada, Caris arrivals continue med-tech IPO hot streak

    BioWorld MedTech
    Omada Health Inc. rang the opening bell on the New York Stock Exchange on June 6, marking its first day as a public company, but it won’t be the most recent IPO...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 3, 2025
  • Red blood cells in an artery with cholesterol

    In two phase IIIs, Merck’s PCSK9 inhibitor cuts cholesterol

    BioWorld
    In two phase III studies, Merck & Co. Inc.’s oral, once monthly proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor produced statistically significant...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe